Send to

Choose Destination

Links from Structure

Structure. 2019 Mar 5;27(3):427-438.e5. doi: 10.1016/j.str.2018.10.027. Epub 2018 Dec 20.

Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists.

Author information

Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstrasse 65, 88397 Biberach, Germany.
LeadXpro AG, PARK InnovAARE, 5234 Villigen, Switzerland.
Swiss Light Source, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstrasse 65, 88397 Biberach, Germany. Electronic address:


We determined two crystal structures of the chemokine receptor CCR2A in complex with the orthosteric antagonist MK-0812. Full-length CCR2A, stabilized by rubredoxin and a series of five mutations were resolved at 3.3 Å. An N- and C-terminally truncated CCR2A construct was crystallized in an alternate crystal form, which yielded a 2.7 Å resolution structure using serial synchrotron crystallography. Our structures provide a clear structural explanation for the observed key role of residue E2917.39 in high-affinity binding of several orthosteric CCR2 antagonists. By combining all the structural information collected, we generated models of co-structures for the structurally diverse pyrimidine amide class of CCR2 antagonists. Even though the representative Ex15 overlays well with MK-0812, it also interacts with the non-conserved H1213.33, resulting in a significant selectivity over CCR5. Insights derived from this work will facilitate drug discovery efforts directed toward highly selective CCR2 antagonists with potentially superior efficacy.


CCR2; GPCR; IMISX in situ crystallization; MK-0812; chemokine receptor; protein engineering; serial crystallography


Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center